Kidney Transplant Clinical Trial
Official title:
Pilot Study to Evaluate the Correlation Between Peripheral Gene Expression Profile Testing, Tissue-based Gene Expression Profiling, Donor Derived Cell Free DNA, and Histopathology Among High-risk Kidney Transplant Recipients
NCT number | NCT05811468 |
Other study ID # | 22060707 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | September 26, 2023 |
Est. completion date | May 30, 2025 |
Verified date | April 2024 |
Source | Rush University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will compare the performance of Gene Expression Profile (GEP)/ Donor derived cell free deoxyribonucleic acid (dd-cfDNA) tests, to the following tests: Molecular Microscope (MMDx) and histopathology (study of changes in tissues caused by disease) in their ability to diagnose (exactly identify) various types of injury within the transplanted kidney.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 30, 2025 |
Est. primary completion date | May 30, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Patients undergoing a for cause biopsy due to ongoing or suspected "injury" of the allograft. - Patients will be between 3 months and 7 years post-transplant episode. - Recipients of both cadaveric and living donor renal transplant are considered eligible. Exclusion Criteria: - No multi organ transplant recipients will be included. - Pregnancy - HIV positive recipients - Recipients of kidney transplant from an identical sibling - Patients with active and biopsy proven BK nephropathy |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center |
United States,
Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9. — View Citation
Gupta G, Moinuddin I, Kamal L, King AL, Winstead R, Demehin M, Kang L, Kimball P, Levy M, Bhati C, Massey HD, Kumar D, Halloran PF. Correlation of Donor-derived Cell-free DNA With Histology and Molecular Diagnoses of Kidney Transplant Biopsies. Transplantation. 2022 May 1;106(5):1061-1070. doi: 10.1097/TP.0000000000003838. Epub 2021 May 28. — View Citation
Park S, Guo K, Heilman RL, Poggio ED, Taber DJ, Marsh CL, Kurian SM, Kleiboeker S, Weems J, Holman J, Zhao L, Sinha R, Brietigam S, Rebello C, Abecassis MM, Friedewald JJ. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2021 Oct;16(10):1539-1551. doi: 10.2215/CJN.05530421. — View Citation
Sigdel TK, Archila FA, Constantin T, Prins SA, Liberto J, Damm I, Towfighi P, Navarro S, Kirkizlar E, Demko ZP, Ryan A, Sigurjonsson S, Sarwal RD, Hseish SC, Chan-On C, Zimmermann B, Billings PR, Moshkevich S, Sarwal MM. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2018 Dec 23;8(1):19. doi: 10.3390/jcm8010019. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantify the number of rejections in the kidney allograft detected via non invasive blood- based testing as reflected in abnormal laboratory readout of GEP value and dd-CFDNA fraction. | The number of rejections in the kidney allograft detected via blood- based non invasive testing will be measured and compared to the number of rejection cases detected by histopathology and MMDX to ascertain accuracy of blood based assays to detect rejection among kidney transplant recipients | Through study completion, an average of 1 year | |
Primary | Quantify the number of rejection cases detected by histopathology and MMDX as reported by respective pathology laboratories/ pathologists | Measure the number of rejections in the kidney allograft detected by histopathology and MMDX as invasive tests and ascertain concordance of those results with blood based non invasive assays. | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087720 -
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
|
Phase 4 | |
Completed |
NCT03749356 -
Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
Completed |
NCT00498576 -
Melatonin and Adiponectin in Hypertensive Kidney Transplant
|
N/A | |
Completed |
NCT00642655 -
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT00374400 -
The Paired Donation Consortium Paired Donation Program
|
N/A | |
Completed |
NCT01710033 -
A Study Of CP-690,550 In Stable Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT00205257 -
Prediction of Acute Rejection in Renal Transplant
|
Phase 1 | |
Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03978494 -
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
|
Phase 1 | |
Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT03644485 -
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT02409901 -
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01047410 -
ACtive Care After Transplantation, the ACT Study
|
N/A | |
Completed |
NCT00940940 -
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
|
Phase 4 | |
Completed |
NCT00217126 -
The Study of Long-term Deterioration of Kidney Transplants.
|
Phase 4 | |
Completed |
NCT00270712 -
A Study of Factors That Affect Long-Term Kidney Transplant Function
|
||
Completed |
NCT00171496 -
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
|
Phase 4 |